| 1 | OMORI K, KOTERA J. Overview of PDEs and their regulation[J]. Circ. Res., 2007, 100(3): 309-327. | 
																													
																							| 2 | ORHAN I E, RAUF A, SALEEM M, et al.. Natural molecules as talented inhibitors of nucleotide pyrophosphatases/phosphodiesterases (PDEs)[J]. Curr. Top. Med. Chem., 2022, 22(3): 209-228. | 
																													
																							| 3 | MAURICE D H, KE H, AHMAD F, et al.. Advances in targeting cyclic nucleotide phosphodiesterases[J]. Nat. Rev. Drug Discov., 2014, 13(4): 290-314. | 
																													
																							| 4 | DANG T A, SCHUNKERT H, KESSLER T. cGMP signaling in cardiovascular diseases: linking genotype and phenotype[J]. J. Cardiovasc. Pharmacol., 2020, 75(6): 516-525. | 
																													
																							| 5 | SAMIDURAI A, XI L, DAS A, et al.. Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities[J/OL]. Pharmacol. Ther., 2021, 226: 107858[2025-02-21]. . | 
																													
																							| 6 | SCHWENKGRUB J, ZAREMBA M, MIROWSKA-GUZEL D, et al.. Ibudilast: a non-selective phosphodiesterase inhibitor in brain disorders[J/OL]. Postępy Hig. Med. Dośw., 2017, 71(1):137-148. | 
																													
																							| 7 | BAILLIE G S, TEJEDA G S, KELLY M P. Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond[J]. Nat. Rev. Drug Discov., 2019, 18(10): 770-796. | 
																													
																							| 8 | SCHAFER P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis[J]. Biochem. Pharmacol., 2012, 83(12): 1583-1590. | 
																													
																							| 9 | 李思杨. 磷酸二酯酶12在结肠癌发生发展中的作用与机制[D]. 厦门: 厦门大学, 2020. | 
																													
																							| 10 | 陈观. 磷酸二酯酶12下调对胃癌的增殖、迁移以及侵袭的影响[D]. 福州: 福建医科大学, 2020. | 
																													
																							| 11 | POULSEN J B, ANDERSEN K R, KJÆR K H, et al.. Human 2'-phosphodiesterase localizes to the mitochondrial matrix with a putative function in mitochondrial RNA turnover[J]. Nucleic Acids Res., 2011, 39(9): 3754-3770. | 
																													
																							| 12 | ESTRELLA M A, DU J, KORENNYKH A. Crystal structure of human nocturnin catalytic domain[J/OL]. Sci. Rep., 2018, 8(1): 16294[2025-02-21]. . | 
																													
																							| 13 | KUBOTA K, NAKAHARA K, OHTSUKA T, et al.. Identification of 2'-phosphodiesterase, which plays a role in the 2-5A system regulated by interferon[J]. J. Biol. Chem., 2004, 279(36): 37832-37841. | 
																													
																							| 14 | PEARCE S F, RORBACH J, VAN HAUTE L, et al.. Maturation of selected human mitochondrial tRNAs requires deadenylation[J/OL]. eLife, 2017, 6: e27596[2025-02-21]. . | 
																													
																							| 15 | RORBACH J, NICHOLLS T J J, MINCZUK M. PDE12 removes mitochondrial RNA poly(A) tails and controls translation in human mitochondria[J]. Nucleic Acids Res., 2011, 39(17): 7750-7763. | 
																													
																							| 16 | SILVERMAN R H. Implications for RNase L in prostate cancer biology[J]. Biochemistry, 2003, 42(7): 1805-1812. | 
																													
																							| 17 | 孙霄麟, 张迪迪, 王馨雅, 等. TOE1敲低和过表达稳转细胞系的构建及其在胃癌细胞中的定位分析[J]. 生物技术进展, 2023, 13(2): 273-281. | 
																													
																							|  | SUN X L, ZHANG D D, WANG X Y, et al.. Construction of stable cell lines with TOE1 knockdown and overexpression and analysis on its cellular localization in gastric cancer cells[J]. Curr. Biotechnol., 2023, 13(2): 273-281. | 
																													
																							| 18 | BRAY F, LAVERSANNE M, SUNG H, et al.. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J. Clin., 2024, 74(3): 229-263. | 
																													
																							| 19 | CHANDRA R, BALACHANDAR N, WANG S, et al.. The changing face of gastric cancer: epidemiologic trends and advances in novel therapies[J]. Cancer Gene Ther., 2021, 28: 390-399. | 
																													
																							| 20 | RUSCH L, ZHOU A, SILVERMAN R H. Caspase-dependent apoptosis by 2', 5'-oligoadenylate activation of RNase L is enhanced by IFN-beta[J]. J. Interferon Cytokine Res., 2000, 20(12): 1091-1100. | 
																													
																							| 21 | SONG X H, LIAO X Y, ZHENG X Y, et al.. Human Ccr4 and Caf1 deadenylases regulate proliferation and tumorigenicity of human gastric cancer cells via modulating cell cycle progression[J/OL]. Cancers, 2021, 13(4): 834[2025-02-21]. . |